Go Deep
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -23,589 | -0.4 | -14.81 | 0.00 | 159.12 |
| Oct 2026 | -23,637 | -0.4 | -14.90 | 0.00 | 160.07 |
| Oct 2026 | -23,832 | -0.4 | -15.26 | 0.00 | 164.03 |
| Oct 2026 | -24,124 | -0.4 | -15.78 | 0.00 | 169.72 |
| Oct 2026 | -23,978 | -0.4 | -15.52 | 0.00 | 166.46 |
| Oct 2026 | -24,465 | -0.4 | -16.40 | 0.00 | 175.57 |
Processa Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -3,265,494.0 | -3,377,179.0 | -3,358,938.0 | -3,436,573.0 |
| EPS | -1.2 | -1.3 | — | -1.8 |
Processa Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -13,563,834.0 | -11,850,118.0 | -11,121,520.0 | -27,424,229.0 | — |
| EPS | -10.4 | -96.8 | -212.0 | -17,025.0 | — |
Processa Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 7,813,567.0 | 3,229,289.0 | 5,786,643.0 | 8,619,851.0 | — |
| Total Liabilities | 2,236,253.0 | 1,533,118.0 | 797,484.0 | 1,149,110.0 | — |
| Total Equity | 5,577,314.0 | 1,696,171.0 | 4,989,159.0 | 7,470,741.0 | — |
Owes vs Owns
Processa Pharmaceuticals, Inc. owed $1.15 for every $1 it owned in Jun 2026, up from $0.13 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.15× | 0.29× | 0.47× | 0.14× | 0.13× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Processa Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 70.9%Other assets 29.1%
How it's funded — Dec 2025
Payables 13.5%Other liabilities 15.1%Shareholders' equity 71.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 5.5 | 1.2 | 4.7 | 6.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.1 | 0.1 | 0.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.3 | 2.0 | 0.9 | 1.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.1 | 0.1 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.1 | 0.2 |
| Payables | 1.1 | 0.9 | 0.3 | 0.3 |
| Other liabilities | 1.2 | 0.6 | 0.3 | 0.6 |
| Shareholders' equity | 5.6 | 1.7 | 5.0 | 7.5 |
| Net tangible assets | 5.6 | 1.7 | 5.0 | 7.5 |
Processa Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -11,385,195.0 | -11,245,042.0 | -8,063,346.0 | -9,605,143.0 | — |
| Investing Activities | -850,000.0 | -3,244.0 | -2,776.0 | 0.0 | — |
| Financing Activities | 16,580,825.0 | 7,733,414.0 | 6,268,724.0 | -388,843.0 | — |